All In Biotech

Drug Trial Radar · NCT00299000

A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

4

Actual

Start

May 2006

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Mar 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, up to 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.

Conditions

  • Mucopolysaccharidosis VI
  • Maroteaux-Lamy Syndrome

Interventions

  • NaglazymeDrug

    Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HeightTime frame: 52 weeks
  2. Change in WeightTime frame: 52 weeks
  3. Change in Haed CircumferenceTime frame: 52 weeks

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Children's Hospital Oakland

    Oakland, California

  • Hospital Femme Mere Enfant Centre

    Lyon, France

  • Hospital PediAtrico de Coimbra

    Coimbra, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.